
Sign up to save your podcasts
Or


Hydroxychloroquine has evolved from a sleepy anti-malaria drug into a partisan litmus test over the future of COVID-19 treatment. Dan and Axios healthcare reporter Bob Herman dig into what we know about the drug, what we still don't, and why both matter.
PLUS: New money for small businesses and a way to help New York medical workers
By Axios4.3
689689 ratings
Hydroxychloroquine has evolved from a sleepy anti-malaria drug into a partisan litmus test over the future of COVID-19 treatment. Dan and Axios healthcare reporter Bob Herman dig into what we know about the drug, what we still don't, and why both matter.
PLUS: New money for small businesses and a way to help New York medical workers

32,087 Listeners

30,693 Listeners

8,783 Listeners

26,261 Listeners

112,144 Listeners

56,553 Listeners

10,287 Listeners

5,202 Listeners

6,090 Listeners

555 Listeners

5,495 Listeners

10,182 Listeners

6,398 Listeners

2,020 Listeners

5,535 Listeners

4,366 Listeners

16,139 Listeners